Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to$21 Million, an Increase of 84% to 93% Compared to Full Year 2022 GAAP Operating Expenses for Full Year 2023 Expected to be in the Range of $30 to$31.5 Million, a Decrease of 47% to 44% Compared to Full Year 2022 PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., ...